Semaglutide vs Liraglutide: Weekly vs Daily GLP-1 for Weight Loss

How They Work

Semaglutide and liraglutide are both GLP-1 receptor agonists. They target the same receptor. They mimic the same gut hormone. But they are structurally different molecules, and that difference changes everything about how they perform in the real world.

GLP-1 (glucagon-like peptide-1) is a hormone your intestines release after a meal. It does three things that matter for weight management. It tells your brain you are full by acting on appetite centers in the hypothalamus. It slows gastric emptying so food sits in your stomach longer, extending the sensation of fullness. And it triggers insulin release from the pancreas in a glucose-dependent manner, helping regulate blood sugar after eating.

The problem with natural GLP-1 is that it self-destructs almost immediately. An enzyme called DPP-4 breaks it down within two to three minutes. That rapid degradation is why researchers had to engineer synthetic versions that could survive in the bloodstream long enough to produce meaningful clinical effects.

Liraglutide was Novo Nordisk's first successful attempt. Approved in 2010 for type 2 diabetes (as Victoza) and in 2014 for chronic weight management (as Saxenda), liraglutide is a modified GLP-1 analog with a fatty acid chain attached at position 26. That fatty acid chain binds to albumin in the blood, shielding the molecule from DPP-4 degradation and extending its half-life to approximately 13 hours. Thirteen hours is a massive improvement over two minutes, but it still means the drug is largely cleared within a day. That is why liraglutide requires daily injections.

Semaglutide came next. Approved in 2017 for diabetes (as Ozempic) and in 2021 for weight management (as Wegovy), semaglutide builds on liraglutide's design but adds critical structural modifications. Novo Nordisk made three key changes to the molecule: they substituted amino acids at two positions to further resist DPP-4 breakdown, and they attached a longer C-18 fatty diacid chain (compared to liraglutide's C-16 fatty acid) that binds more tightly to albumin. The result is a half-life of approximately 165 hours -- roughly seven days. One injection per week maintains steady-state receptor activation that liraglutide cannot match.

The half-life difference is not a minor convenience upgrade. It fundamentally changes the pharmacodynamics. Liraglutide produces a peak-and-trough pattern. Drug levels rise after injection, peak around 8-12 hours, then decline. By the time the next day's injection arrives, blood levels have dropped significantly. Semaglutide, by contrast, reaches steady state after four to five weeks of weekly dosing and then maintains relatively stable blood levels with minimal fluctuation between doses. That consistent receptor occupancy translates to more sustained appetite suppression, more consistent blood sugar control, and -- as the clinical data shows -- substantially greater weight loss.

Both medications are administered as subcutaneous injections using prefilled pen devices. Liraglutide is injected daily, with doses titrated from 0.6 mg up to 3.0 mg for weight management. Semaglutide is injected weekly, titrated from 0.25 mg up to 2.4 mg for weight management. The injection itself is comparable -- a small needle, minimal discomfort, takes about 30 seconds. The difference is doing it every day versus once a week.

What the Research Shows

The clinical evidence for both medications is robust. But the data is not close. Semaglutide produces roughly double the weight loss of liraglutide in comparable populations.

Liraglutide: The SCALE Trial Program. The SCALE (Satiety and Clinical Adiposity -- Liraglutide Evidence) trials were the foundation for Saxenda's approval. SCALE Obesity and Prediabetes, published in the New England Journal of Medicine in 2015 (PMID: 26132939), enrolled 3,731 adults without diabetes who had a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Over 56 weeks, participants on liraglutide 3.0 mg lost an average of 8.0% of their body weight, compared to 2.6% with placebo. Approximately one-third of participants achieved weight loss of 10% or more. An additional finding: 60% of participants with prediabetes at baseline reverted to normal glucose tolerance, compared to 33% in the placebo group.

SCALE Diabetes studied liraglutide in adults with type 2 diabetes and obesity. Weight loss was more modest at 6.0% (liraglutide 3.0 mg) versus 2.0% (placebo) over 56 weeks. SCALE Maintenance examined whether liraglutide could sustain weight loss after an initial low-calorie diet phase. Participants who had already lost at least 5% of body weight through diet alone were randomized to liraglutide or placebo. The liraglutide group maintained their weight loss and lost an additional 6.2%, while the placebo group regained weight. These trials established liraglutide as a legitimate pharmaceutical tool for weight management -- a meaningful advancement for its time.

Semaglutide: The STEP Trial Program. The STEP (Semaglutide Treatment Effect in People with Obesity) trials raised the bar significantly. STEP 1, published in the New England Journal of Medicine in 2021 (PMID: 33567185), enrolled 1,961 adults with obesity or overweight with comorbidities, without diabetes. Over 68 weeks, participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight, compared to 2.4% with placebo. One-third of participants lost more than 20% of their body weight. These results nearly doubled what SCALE had achieved with liraglutide.

STEP 2 studied semaglutide in adults with type 2 diabetes and showed 9.6% weight loss. STEP 3 combined semaglutide with intensive behavioral therapy and reached 16.0%. STEP 5 extended observation to 104 weeks, demonstrating sustained weight loss of approximately 15% at two years with continued treatment. Across the board, semaglutide at 2.4 mg outperformed what liraglutide at 3.0 mg had achieved in any comparable trial.

The Head-to-Head: STEP 8. This is the trial that settles the comparison directly. STEP 8, published in JAMA in 2022 (PMID: 35015037), was a randomized, open-label, head-to-head trial comparing semaglutide 2.4 mg (once weekly) to liraglutide 3.0 mg (once daily) in 338 adults with obesity or overweight who did not have diabetes. This was not a cross-trial comparison or an indirect inference. This was the same patients, the same timeframe, the same endpoints, randomly assigned to one drug or the other.

At 68 weeks, the results were unambiguous. Semaglutide produced an average body weight reduction of 15.8%. Liraglutide produced 6.4%. Semaglutide more than doubled liraglutide's weight loss in the same population over the same period. The estimated treatment difference was -9.4 percentage points in favor of semaglutide (95% CI, -12.0 to -6.8; P<0.001).

Looking at clinically meaningful thresholds reinforces the gap. In STEP 8, 70.9% of semaglutide participants achieved at least 10% weight loss, compared to 25.6% of liraglutide participants. For 20% or more weight loss, 55.0% of the semaglutide group hit that mark versus just 7.0% on liraglutide. For a 250-pound person, the difference translates to roughly 40 pounds lost on semaglutide versus 16 pounds on liraglutide. The gap is clinically significant by any standard.

Cardiovascular Outcomes: SELECT vs LEADER. Semaglutide and liraglutide have both been studied in dedicated cardiovascular outcomes trials, but the results differ in scope and strength.

The LEADER trial (PMID: 27295427), published in the New England Journal of Medicine in 2016, enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk. Over a median follow-up of 3.8 years, liraglutide 1.8 mg (the diabetes dose, not the 3.0 mg obesity dose) reduced major adverse cardiovascular events (MACE -- a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke) by 13% compared to placebo (hazard ratio 0.87, 95% CI 0.78-0.97). This was a meaningful finding that established liraglutide as the first GLP-1 agonist with proven cardiovascular benefit in diabetic patients.

The SELECT trial (PMID: 37952131), published in 2023, was larger and studied a different population. It enrolled 17,604 adults aged 45 and older with established cardiovascular disease, a BMI of 27 or above, and -- critically -- without diabetes. Semaglutide 2.4 mg reduced MACE by 20% compared to placebo (hazard ratio 0.80, 95% CI 0.72-0.90) over a median follow-up of 39.8 months. SELECT was the first trial to demonstrate cardiovascular risk reduction with a GLP-1 agonist in patients without diabetes, and the absolute risk reduction was larger than what LEADER achieved.

The LEADER trial studied a lower dose of liraglutide (1.8 mg) in a diabetic population. SELECT studied a higher dose of semaglutide (2.4 mg) in a non-diabetic population with established heart disease. Direct comparison is imperfect because the populations differ. But the signal is consistent: semaglutide at its obesity dose produced a larger cardiovascular risk reduction than liraglutide at its diabetes dose.

Side Effects and Tolerability

Both medications cause gastrointestinal side effects. This is inherent to the GLP-1 mechanism. Slowing gastric emptying and suppressing appetite comes at a cost, and that cost is primarily nausea, vomiting, diarrhea, and constipation. The question is how the two compare in severity and frequency.

Nausea is the most common side effect for both. In STEP 8, the head-to-head trial, nausea occurred in 43.9% of semaglutide participants and 38.2% of liraglutide participants. Vomiting was reported in 26.0% versus 12.9%. Diarrhea hit 21.1% of the semaglutide group and 18.9% of the liraglutide group. Constipation was 16.3% versus 13.2%. These numbers suggest semaglutide causes somewhat more nausea and vomiting, while other GI symptoms are relatively comparable.

There is a reasonable clinical argument that liraglutide may be slightly easier to tolerate for sensitive patients. Its lower potency means the GI effects are milder on average. Its daily dosing also allows for more granular dose adjustments. If a patient is struggling with nausea on liraglutide, they can step back from 1.8 mg to 1.2 mg or from 2.4 mg to 1.8 mg in small increments. Semaglutide's dose steps are further apart and the weekly dosing means any adjustment takes longer to manifest. Some clinicians prefer to start GLP-1-naive patients on liraglutide as a "gentle introduction" to the drug class before transitioning to semaglutide if tolerated.

Injection frequency is a real quality-of-life factor. Injecting daily is not painful, but it is a commitment. It requires carrying the pen, remembering every day, and building the habit into a daily routine. Some patients find this manageable. Others find it a significant burden over months and years of treatment. Weekly dosing with semaglutide eliminates six out of seven injection days. For adherence, this matters. In STEP 8, treatment discontinuation due to adverse events was 3.5% for semaglutide and 12.6% for liraglutide. That gap likely reflects both the side effect difference and the dosing burden difference.

Serious adverse events are uncommon with both medications. Pancreatitis occurs at rates below 0.5% in major trials for both drugs and has not been statistically different from placebo. Gallbladder events (gallstones, cholecystitis) occur at slightly elevated rates with both, consistent with rapid weight loss from any cause. Both medications carry the same FDA boxed warning about medullary thyroid carcinoma risk based on rodent studies. This finding has not been replicated in humans in over a decade of post-market surveillance for liraglutide (which has been available since 2010) or in the growing semaglutide surveillance data.

Liraglutide's longest advantage: time on the market. Liraglutide has been prescribed to millions of patients since 2010. That is 16 years of real-world safety data, pharmacovigilance reports, and post-marketing studies. Semaglutide has been available since 2017 (nine years), with the higher obesity dose since 2021 (five years). Both have extensive safety records, but liraglutide's longer track record provides additional reassurance for patients and prescribers who prioritize long-term safety data above all else.

Muscle loss applies to both, as it does to all GLP-1 agonists. Weight loss from any intervention -- pharmaceutical, surgical, or dietary -- involves some loss of lean body mass. Neither semaglutide nor liraglutide selectively targets fat. The standard recommendation with both medications is to maintain adequate protein intake (at least 1.0-1.2 grams per kilogram of body weight daily) and engage in resistance training at least twice per week. Patients who follow these guidelines consistently show better body composition outcomes than those who rely on the medication alone.

Cost, Access, and Practical Considerations

Both semaglutide and liraglutide are brand-name medications with significant list prices. Insurance coverage, compounding availability, and regulatory dynamics all influence which one a patient can realistically access.

Brand-name pricing is comparable in monthly cost. Wegovy (semaglutide 2.4 mg weekly for obesity) lists at approximately $1,350 per month. Saxenda (liraglutide 3.0 mg daily for obesity) lists at roughly $1,350-1,400 per month. The diabetes versions -- Ozempic (semaglutide) and Victoza (liraglutide) -- are in the $900-1,100 per month range. Without insurance or manufacturer savings programs, both are prohibitively expensive for most patients. Novo Nordisk offers savings cards for both that can reduce copays for commercially insured patients, but eligibility varies and government insurance (Medicare, Medicaid) patients typically do not qualify.

Insurance coverage favors semaglutide in 2026. This may seem counterintuitive given liraglutide's longer market presence, but the superior clinical data for semaglutide has shifted payer behavior. Many commercial insurance formularies now prefer semaglutide (Wegovy) over liraglutide (Saxenda) for anti-obesity medication coverage. Some plans have removed Saxenda from their formularies entirely. For patients with type 2 diabetes, Ozempic generally has stronger formulary positioning than Victoza, again reflecting the more recent and more impressive clinical trial results. That said, coverage varies widely by plan and region. Some patients may find Saxenda is the only covered option on their specific formulary. Always check with your insurer before assuming availability.

Compounded versions exist for both. When semaglutide was placed on the FDA Drug Shortage List, compounding pharmacies began producing semaglutide at significantly lower prices, typically $150-400 per month. Liraglutide compounding has been less widespread because the shortage situation has been different, but compounded liraglutide is available from some pharmacies. The compounding regulatory landscape continues to evolve as the FDA addresses shortage designations and manufacturers challenge compounding access. Patients using compounded versions should verify their pharmacy is properly licensed (503A with a patient-specific prescription, or 503B outsourcing facility registered with the FDA) and should stay informed about regulatory changes that could affect availability.

Switching between the two is straightforward. Patients transitioning from liraglutide to semaglutide (or vice versa) do not need a washout period. The standard clinical approach is to stop the outgoing medication and begin the new one at the lowest starting dose, following the full titration schedule. Some prescribers may accelerate titration slightly for patients who previously tolerated a GLP-1 agonist well, but this is a case-by-case clinical judgment. The most common switching scenario in practice is a patient who starts on liraglutide, tolerates it well, and then transitions to semaglutide for greater efficacy. This stepped approach can work well for patients who are anxious about GLP-1 side effects or who want to confirm tolerability before committing to the more potent option.

The Bottom Line

Semaglutide is the clear winner on efficacy and convenience. The STEP 8 head-to-head trial removes any ambiguity: semaglutide produces more than double the weight loss of liraglutide in the same population. It requires one injection per week instead of one per day. It has stronger cardiovascular outcomes data from the SELECT trial. And treatment discontinuation rates are lower, suggesting better real-world adherence.

Liraglutide is not a bad medication. It was a genuine breakthrough when it arrived. The SCALE trials demonstrated meaningful weight loss that exceeded anything previously available in pharmaceutical obesity treatment. For a patient who has never used a GLP-1 agonist and is nervous about side effects, liraglutide's lower potency and more granular daily dose adjustments offer a gentler starting point. Its 16-year safety record is the longest of any GLP-1 agonist on the market. And for the subset of patients who respond unusually well to liraglutide -- some individuals do -- switching may not be necessary.

But for most people starting GLP-1 therapy for weight management in 2026, semaglutide is the standard of care. The efficacy gap is too large to ignore. Roughly 15-17% average body weight loss versus 6-8%. Weekly dosing versus daily. Cardiovascular risk reduction of 20% demonstrated in patients without diabetes. These are not marginal differences.

The practical question for many patients will not be which drug is more effective -- the data answers that clearly -- but which one they can access. Insurance coverage, pharmacy stock, compounding availability, and out-of-pocket cost still dictate treatment decisions for millions of people. If your insurance covers semaglutide and it is in stock, the clinical case for starting there is strong. If liraglutide is your only covered option, it remains a legitimate and effective tool that will produce meaningful weight loss for most patients. Either way, the medication works best when combined with dietary changes, adequate protein intake, resistance training, and ongoing medical supervision.

Talk to your doctor. They can evaluate your medical history, check your insurance formulary, and recommend the option that fits your clinical profile and practical situation.